Treats edema. ANDA 205609, held by Adaptis. Ethacrynic Acid.
As of Nov 16, 2026, ANDA 205609 (Ethacrynic Acid), held by Adaptis, was first approved by FDA on Jun 30, 2016, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Ethacrynic Acid Tablets USP are indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. Intravenous ethacrynate sodium is indicated when a rapid onset of diuresis is desired, e.g.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 30, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ethacrynic Acid25MG · tablet;oral | Ethacrynic Acid | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters